Compare DIN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | ASMB |
|---|---|---|
| Founded | 1958 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 553.6M |
| IPO Year | 1991 | 2010 |
| Metric | DIN | ASMB |
|---|---|---|
| Price | $36.86 | $31.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $30.67 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 455.6K | 152.7K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $866,500,000.00 | $37,191,000.00 |
| Revenue This Year | $10.69 | $33.33 |
| Revenue Next Year | $2.20 | N/A |
| P/E Ratio | $16.12 | ★ N/A |
| Revenue Growth | 6.47 | ★ 31.30 |
| 52 Week Low | $18.63 | $7.75 |
| 52 Week High | $37.24 | $39.71 |
| Indicator | DIN | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | 41.12 |
| Support Level | $31.26 | $31.73 |
| Resistance Level | $34.22 | $34.69 |
| Average True Range (ATR) | 1.29 | 2.13 |
| MACD | 0.14 | -0.38 |
| Stochastic Oscillator | 92.90 | 17.43 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.